The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: A pilot study

Gynecological Endocrinology

Volumn 28, Issue 7, 2012, Pages 559-561

  Pashov, Alexandr I ^a   Tskhay, Vitaly B ^a   Ionouchene, Svetlana V ^b  

^a KRASNOYARSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^b SCIENTIFIC CENTRE FOR FAMILY HEALTH AND HUMAN REPRODUCTION PROBLEMS   (Russian Federation)

Author keywords

Atypical endometrial hyperplasia; GnRH agonists; Levonorgestrel intrauterine hormonal system; Well differentiated endometrial adenocarcinoma

Indexed keywords

LEUPRORELIN; LEVONORGESTREL; METFORMIN;

ADULT; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DRUG DOSE INCREASE; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONAL THERAPY; HUMAN; METABOLIC SYNDROME X; ORGAN PRESERVATION; PILOT STUDY; PRIORITY JOURNAL;

ADENOCARCINOMA; ADMINISTRATION, INTRAVAGINAL; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; LEUPROLIDE; LEVONORGESTREL; NEOPLASM STAGING; ORGAN SPARING TREATMENTS; PILOT PROJECTS; PROGESTINS; YOUNG ADULT;

EID: 84862873857     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.649813     Document Type: Article

References (24)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer inciDence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592.
2. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer inciDence in five continents. Vol. VIII. Lyon: IARC Press; 2002. pp 310-486.
3. Bray F, Dos Santos Silva I, Moller H, WeiDerpass E. Endometrial cancer inciDence trends in Europe: unDerlying Determinants and. prospects for prevention. Cancer EpiDemiol Biomarkers Prev 2005;14:1132-1142. (Pubitemid 40656458)
4. Pashov AI, Diduk OV. The nature of a cancer of a body of a uterus in Krasnoyarsk edge. Obstetrics and Gynecology Pressing Questions: The Collection of Proceedings. Krasnoyarsk, 2009; 93-98.
5. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002;99:709-719. (Pubitemid 34442445)
6. Chernukha GE, Shigoreva TV, Mogirevskay OA. The effect of levonorgestrel releasing intrauterine system on endometrial hyperplasia. Gynecol Endocrinol 2006;22:255.
7. Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009;113:1104-1116.
8. Petta CA, Ferriani RA, Abrao MS, Hassan D, Rosa E Silva JC, Podgaec S, BahamonDes L. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a Depot GnRH analogue for the reatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005;20:1993-1998. (Pubitemid 40932389)
9. Orbo A, Arnes M, Pettersen I, Larsen K, Hanssen K, Moe B. Downregulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system. Acta Obstet Gynecol Scand 2010;89:1438-1446.
10. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrelreleasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:547. e1-547.10.
11. Schriock ED. GnRH agonists. Clin Obstet Gynecol 1989;32:550-563. (Pubitemid 19251182)
12. Holland C. Unresolved issues in the management of endometrial cancer. Expert Rev Anticancer Ther 2011;11:57-69.
13. Bokhman JV, Chepick OF, Volkova AT, Vishnevsky AS. Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol Oncol 1985;20:139-155. (Pubitemid 15133008)
14. Jeyarajah AR, Gallagher CJ, Blake PR, Oram DH, Dowsett M, Fisher C, Oliver RT. Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol 1996;63:47-52. (Pubitemid 26337964)
15. Covens A, Thomas G, Shaw P, Ackerman I, Osborne R, Lukka H, Carey M, et al. A phase II study of leuproliDe in adVanced/recurrent endometrial cancer. Gynecol Oncol 1997;64:126-129. (Pubitemid 27026969)
16. Asbury RF, Brunetto VL, Lee RB, Reid G, Rocereto TF; Gynecologic Oncology Group. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 2002;25:557-560. (Pubitemid 35453658)
17. Kohzo A, Misa D, Yumiko I, Seiichiro O. Differences between gonadotropin-releasing hormone agonist and oral contraceptives for the treatment of endometriosis. Obstet Gynecol 2005;105:63S.
18. Ayse S, Baris A, Bilhan S, Bulent U. Medical treatment of uterocutaneous fistula with gonadotropin-releasing hormone agonist administration. Obstet Gynecol 2008;111(2 Pt 2);526-528.
19. Mamoru M, Takashi Y, HiDeto Y, Hisanori M. Effect of Gonadotropin- Releasing Hormone Agonist on a Uterine Arteriovenous Malformation. Obstet Gynecol 2006;108(3 Pt 2):751-753.
20. Farthing A. Conserving fertility in the management of gynaecological cancers. BJOG 2006;113:129-134.
21. CaDe TJ, Quinn MA, Rome RM, Neesham D. Progestogen treatment options for early endometrial cancer. BJOG 2010;117:879-884.
22. Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 2009;19:1068-1073.
23. Signorelli M, Caspani G, Bonazzi C, Chiappa V, Perego P, Mangioni C. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG 2009;116:114-118.
24. Corrado G, Baiocco E, Carosi M, Vizza E. Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report. Fertil Steril 2008;90:2006.e5-2006.e8.